Last reviewed · How we verify
SPH 3348
At a glance
| Generic name | SPH 3348 |
|---|---|
| Sponsor | Shanghai Pharmaceuticals Holding Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPH 3348 CI brief — competitive landscape report
- SPH 3348 updates RSS · CI watch RSS
- Shanghai Pharmaceuticals Holding Co., Ltd portfolio CI